New Zealand markets close in 5 hours 51 minutes

Bio-Techne Corporation (TECH)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
518.77+7.94 (+1.55%)
At close: 4:00PM EDT
518.18 -0.59 (-0.11%)
After hours: 05:22PM EDT

Bio-Techne Corporation

614 McKinley Place N.E.
Minneapolis, MN 55413
United States
612 379 8854

Full-time employees2,600

Key executives

NameTitlePayExercisedYear born
Mr. Charles R. KummethCEO, Pres & Director4.69M26.94M1960
Mr. James T. HippelExec. VP of Fin. & CFO1.71M17.22M1971
Ms. Brenda S. Furlow J.D.Exec. VP, Gen. Counsel, Sec. & Chief Compliance Officer1.27M6.89M1958
Mr. Norman David EansorPres of Protein Sciences Segment1.6M9.03M1961
Mr. Kim KeldermanPres of Diagnostics & Genomics1.45MN/A1967
David ClairSr. Director of Investor Relations & Corp. Devel.N/AN/AN/A
Mr. Gerry AndrosVP of Sales and MarketingN/AN/AN/A
Mr. Robert M. GavinVP of Corp. Devel.N/AN/A1968
Mr. Struan RobertsonVP of HRN/AN/AN/A
Mr. Kevin S. GouldSr. VP of Diagnostics Reagents DivisionN/AN/A1966
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment provides diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and nucleic acid analysis products for use in diagnostic or research applications, as well as instruments and process control products for hematology, blood chemistry, blood gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Novus Biologicals, Tocris Biosciences, ProteinSimple, Advanced Cell Diagnostics, and ExosomeDx brands. Bio-Techne Corporation has a clinical research collaboration with Carterra Inc. for the study of COVID-19 variants. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Corporate governance

Bio-Techne Corporation’s ISS governance QualityScore as of 26 September 2021 is 1. The pillar scores are Audit: 5; Board: 2; Shareholder rights: 1; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.